Details for New Drug Application (NDA): 210686
✉ Email this page to a colleague
NDA 210686 describes ABIRATERONE ACETATE, which is a drug marketed by Amneal Pharms, Apotex, Dr Reddys, Florida, Glenmark Speclt, Hikma, MSN, Mylan, Novugen, Qilu, Rising, Teva Pharms Usa, and Wockhardt Bio Ag, and is included in fifteen NDAs. It is available from twenty-three suppliers. Additional details are available on the ABIRATERONE ACETATE profile page.
The generic ingredient in ABIRATERONE ACETATE is abiraterone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.
The generic ingredient in ABIRATERONE ACETATE is abiraterone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.
Summary for 210686
| Tradename: | ABIRATERONE ACETATE |
| Applicant: | Msn |
| Ingredient: | abiraterone acetate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 210686
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 210686 | ANDA | BluePoint Laboratories | 68001-489 | 68001-489-07 | 120 TABLET in 1 BOTTLE (68001-489-07) |
| ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 210686 | ANDA | BluePoint Laboratories | 68001-673 | 68001-673-06 | 60 TABLET in 1 BOTTLE (68001-673-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | Jul 10, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Apr 24, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
